Association of CCL13 Levels in Serum and Synovial Fluid with the Radiographic Severity of Knee Osteoarthritis

Gao, Feng; Tian, Jun; Pan, Haile; Gao, Þ Jun; Ye, Meng

doi:10.1097/jim.0000000000000150

Cited by 15 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional CC chemokines are modulated in human joint injury and OA. Some of these studies show interesting correlations with radiographic severity 24,25 suggesting 736 SCANZELLO potential biomarker utility. Others have been implicated in disease pathogenesis in animal models 26 but the relevance to human disease is unclear.…”

Section: Ccl19/21mentioning

confidence: 99%

Chemokines and inflammation in osteoarthritis: Insights from patients and animal models

Scanzello

2017

Journal Orthopaedic Research

167

140

View full text Add to dashboard Cite

Evidence has been building that the pathologic drive for development of osteoarthritis (OA) involves more than simple mechanical “wear and tear.” Inflammatory mechanisms play an important role in the tissue response to joint injury, and are involved in development of post-traumatic OA. Inflammation also appears integral to the progression of OA, whether post-traumatic or spontaneous, contributing to the evolution of joint tissue degradation and remodeling as well as joint pain. Both patient-based studies and in vivo models of disease have shed light on a number of inflammatory pathways and mediators that impact various aspects of this disease, both structurally and symptomatically. Recent work in this field has implicated inflammatory chemokines in osteoarthritis pathogenesis. Expression of multiple chemokines and their receptors is modulated during disease in both patients and animal models. Although best known for their effects on leukocyte migration and trafficking within the immune system, chemokines can have a wide variety of effects on both motile and non-motile cell types, impacting proliferation, differentiation, and activation of cellular responses. Their role in OA models has also demonstrated diverse effects on disease that exemplify their wide-ranging effects. Understanding how these important mediators of inflammation impact joint disease, and whether they can be targeted therapeutically, is actively being investigated by many groups in this field. This narrative review focuses on evidence published within the last 5 years highlighting chemokine-mediated pathways with mechanistic involvement in osteoarthritis and joint tissue repair.

show abstract

Section: Ccl19/21mentioning

confidence: 99%

Chemokines and inflammation in osteoarthritis: Insights from patients and animal models

Scanzello

2017

Journal Orthopaedic Research

167

140

View full text Add to dashboard Cite

show abstract

“…They mostly involved inflammatory parameters which have shown a positive correlation with disease severity evaluated by X-ray of the targeted joint. [60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75] Interestingly, such associations could not be observed when the same markers were measured in the serum, suggesting that SF measurements may be more sensitive than systemic assessments likely due to the lower specificity for articular metabolism.…”

Section: N-propeptidementioning

confidence: 99%

Soluble biological markers in osteoarthritis

Rousseau

Chapurlat

Garnero

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

In recent years, markers research has focused on the structural components of cartilage matrix. Specifically, a second generation of degradation markers has been developed against type II collagen neoepitopes generated by specific enzymes. A particular effort has been made to measure the degradation of minor collagens III and X of the cartilage matrix. However, because clinical data, including longitudinal controlled studies, are very scarce, it remains unclear whether they will be useful as an alternative to or in combination with current more established collagen biological markers to assess patients with osteoarthritis (OA). In addition, new approaches using high-throughput technologies allowed to detect new types of markers and improve the knowledge about the metabolic changes linked to OA. The relative advances coming from phenotype research are a first attempt to classify the heterogeneity of OA, and several markers could improve the phenotype characterization. These phenotypes could improve the selection of patients in clinical trials limiting the size of the studies by selecting patients with OA characteristics corresponding to the metabolic pathway targeted by the molecules evaluated. In addition, the inclusion of rapid progressors only in clinical trials would facilitate the demonstration of efficacy of the investigative drug to reduce joint degradation. The combination of selective biochemical markers appears as a promising and cost-effective approach to fulfill this unmet clinical need. Among the various potential roles of biomarkers in OA, their ability to monitor drug efficacy is probably one of the most important, in association with clinical and imaging parameters. Biochemical markers have the unique property to detect changes in joint tissue metabolism within a few weeks.

show abstract

“…Afterwards, further 32 articles were excluded, either because they were reviews, studies not written in English, studies that described biomarkers not obtained from SF samples, or studies that included other diseases without reporting about OA. Thus, 159 articles 12,15…”

Section: Resultsmentioning

confidence: 99%

Synovial Fluid Biomarkers in Knee Osteoarthritis: A Systematic Review and Quantitative Evaluation Using BIPEDs Criteria

et al. 2020

View full text Add to dashboard Cite

Objective The aim of this systematic review was to analyze the evidence about the efficacy of the several synovial fluid (SF) biomarkers proposed for knee osteoarthritis (OA), categorizing them by both molecular characteristics and clinical use according to the BIPEDs criteria, to provide a comprehensive and structured overview of the current literature. Design A systematic review was performed in May 2020 on PubMed, Cochrane Library, and Embase databases about SF biomarkers in patients with knee OA. The search was limited to articles in the last 20 years on human studies, involving patients with knee OA, reporting SF biomarkers. The evidence for each selected SF biomarker was quantified according to the 6 categories of BIPEDs classification. Results A total of 159 articles were included in the qualitative data synthesis and 201 different SF biomarkers were identified. Among these, several were investigated multiple times in different articles, for a total of 373 analyses. The studies included 13,557 patients with knee OA. The most promising SF biomarkers were C4S, IL-6, IL-8, Leptin, MMP-1/3, TIMP-1, TNF-α, and VEGF. The “burden of disease” and “diagnostic” categories were the most represented with 132 and 106 different biomarkers, respectively. Conclusions The systematic review identified numerous SF biomarkers. However, despite the high number of studies on the plethora of identified molecules, the evidence about the efficacy of each biomarker is supported by limited and often conflicting findings. Further research efforts are needed to improve the understanding of SF biomarkers for a better management of patients with knee OA.

show abstract

Association of CCL13 Levels in Serum and Synovial Fluid with the Radiographic Severity of Knee Osteoarthritis

Abstract: CCL13 levels in serum and SF were correlated with the radiographic severity of OA. CCL13 levels in serum and SF may serve as a biomarker for the progression of OA.

Cited by 15 publications

References 21 publications

Chemokines and inflammation in osteoarthritis: Insights from patients and animal models

Chemokines and inflammation in osteoarthritis: Insights from patients and animal models

Soluble biological markers in osteoarthritis

Synovial Fluid Biomarkers in Knee Osteoarthritis: A Systematic Review and Quantitative Evaluation Using BIPEDs Criteria

Contact Info

Product

Resources

About